scholarly journals Addressing decisional conflict about fertility preservation: helping young female cancer survivors’ family planning decisions

2017 ◽  
Vol 44 (3) ◽  
pp. 175-180 ◽  
Author(s):  
Madleina Müller ◽  
Corinne Urech ◽  
Jacky Boivin ◽  
Verena Ehrbar ◽  
Rebecca Moffat ◽  
...  

BackgroundHealth professionals are challenged by a growing number of young long-term cancer survivors with their specific needs with regard to family planning. This study aimed at assessing decisional conflict (DC) in young female cancer patients regarding fertility preservation, identifying demographic, fertility and fertility preservation related factors, which may affect DC, and assessing the helpfulness of various decision-supports.MethodsA retrospective, cross-sectional, web-based survey via an online questionnaire available in three languages with specific items concerning cancer, fertility, fertility preservation and the validated Decisional Conflict Scale targeted at current or former female cancer patients aged 18–45 years, with cancer types or treatment potentially affecting reproductive function.ResultsThe 155 participating women showed considerable DC, especially with regard to missing information and support. DC was significantly lower in patients when the risk of infertility was discussed with a health professional, when they had undergone any procedure to preserve fertility, and when they had a university education. A longer time interval since cancer diagnosis was associated with higher DC. The most helpful decision-support tools were specialised websites and leaflets.ConclusionsYoung female cancer patients’ DC with regard to fertility preservation is very high. Information and support seem to be deficient. More information through standardised information tools might be an effective strategy to lower their DC at the time when treatment decisions need to be taken, and to improve their reproductive health after they have overcome cancer in the future.

10.5772/24932 ◽  
2012 ◽  
Author(s):  
R. Gerritse ◽  
L. Bastings ◽  
C.C.M. Beerendonk ◽  
J.R. Westphal ◽  
D.D.M. Braat ◽  
...  

2008 ◽  
Vol 4 ◽  
pp. 79
Author(s):  
Marie-Madeleine Dolmans ◽  
Jacques Donnez ◽  
◽  


2018 ◽  
Vol 7 (1) ◽  
pp. 30-36 ◽  
Author(s):  
Verena Ehrbar ◽  
Corinne Urech ◽  
Christoph Rochlitz ◽  
Rosanna Zanetti Dällenbach ◽  
Rebecca Moffat ◽  
...  

2019 ◽  
Vol 34 (8) ◽  
pp. 1462-1469 ◽  
Author(s):  
Claudia Massarotti ◽  
Paola Scaruffi ◽  
Matteo Lambertini ◽  
Fausta Sozzi ◽  
Valentino Remorgida ◽  
...  

Abstract STUDY QUESTION Are there reasons that motivate young cancer survivors to ask for follow-up visits at an oncofertility unit? SUMMARY ANSWER Cancer survivors request oncofertility follow-up visits for the management of treatment-related side effects or ovarian reserve evaluation, even if not (or not yet) wishing for a pregnancy. WHAT IS KNOWN ALREADY Personalised oncofertility counselling before gonadotoxic therapies is considered standard of care for young women with newly diagnosed cancer. However, the long-term follow-up of these patients in an oncofertility unit is not described in the literature other than for the use of cryopreserved material. STUDY DESIGN, SIZE, DURATION We retrospectively examined rates and reasons for the first follow-up visits of 154 consecutive young female cancer patients (age range: 18–40 years) who underwent a pre-treatment consultation between January 2012 and June 2017. Demographic and clinical data were collected, as well as information about the chosen fertility preservation method, if any. PARTICIPANTS/MATERIALS, SETTING, METHODS Rates and reasons for follow-up visits were collected and expressed as percentages. Different reasons were examined in the whole cohort and stratified for type of malignancy. Possible predictive factors for return to the follow-up visit (age, nulliparity, presence of a partner, neoplasm, having cryopreserved material) were investigated through logistic regression. MAIN RESULTS AND THE ROLE OF CHANCE Out of 154 patients, 74 returned to the oncofertility unit (48.1%) for a follow-up visit. The first visit was requested mostly at the end of anticancer therapies (51.3% versus 40.5% during therapies and 8.1% after cancer relapse). Among these patients, only 10.8% returned for the first time because they were actively desiring a pregnancy. For the others, the most common reasons for consultations were management of gynecological adverse effects of therapies (29.7%) and evaluation of ovarian reserve not linked to an immediate desire for a pregnancy (39.2%). Other patients asked for contraception (4.1%), menopause counselling (5.4%), or new fertility preservation counselling because of cancer relapse (10.8%). None of the examined factors were significantly predictive of return to the oncofertility unit. LIMITATIONS, REASONS FOR CAUTION These findings represent the experience of a single centre. A longer duration of follow-up would be needed to provide more precise information on this regard. WIDER IMPLICATION OF THE FINDINGS The role of an oncofertility unit should not be limited to proposing fertility preservation procedures. In the management of young adult cancer patients, the reproductive medical specialist should be considered a key figure not only before but also during and after anticancer treatments to explore salient aspects of gynecological and reproductive health. STUDY FUNDING/COMPETING INTEREST(S) This research did not receive any specific funding. M.L. served as a consultant for Teva and received honoraria from Theramex outside the submitted work. The other authors declare no conflict of interest. TRIAL REGISTRATION NUMBER N.A.


2017 ◽  
Vol 21 (1) ◽  
pp. 45-51 ◽  
Author(s):  
Corinne Urech ◽  
Verena Ehrbar ◽  
Jacky Boivin ◽  
Madleina Müller ◽  
Judith Alder ◽  
...  

2019 ◽  
Vol 34 (9) ◽  
pp. 1726-1734 ◽  
Author(s):  
Verena Ehrbar ◽  
Corinne Urech ◽  
Christoph Rochlitz ◽  
Rosanna Zanetti Dällenbach ◽  
Rebecca Moffat ◽  
...  

Abstract Study question Does the use of an online decision aid (DA) about fertility preservation (FP), in addition to standard counselling by a specialist in reproductive medicine, reduce decisional conflict compared to standard counselling alone? Summary answer Female cancer patients who could make use of the online DA had a significantly lower short-term decisional conflict score. What is known already Nowadays, female cancer patients have several options for preserving fertility, but having to decide whether to opt for FP within a short time frame after cancer diagnosis and before the start of treatment is challenging. According to previous studies focussing mainly on breast cancer patients, decisional conflict among these women is high, and they have expressed the need for additional support. Study design, size, duration The study was a randomized controlled trial including female cancer patients who were referred by their treating oncologist to a specialist in reproductive medicine for fertility counselling. Participants were randomly assigned to the control group (counselling only) or to the intervention group (counselling and additional use of the online DA immediately after counselling). Recruitment was ongoing from July 2016 to December 2017 at eight fertility centres in Switzerland and Germany. Participants/materials, setting, methods The online DA was developed by an interdisciplinary team of specialists in reproductive medicine, gynaecologists, oncologists and psychologists. Of 79 recruited participants, 59 completed the first assessment and could therefore be enrolled in the study. They were asked to complete an online questionnaire at three time points: at T1, after counselling (control group, n = 27) or after counselling and the additional use of the DA (intervention group, n = 24); at T2, 1 month later (N = 41: control group, n = 23; intervention group, n = 18); and at T3, 12 months later (N = 37: control group, n = 20; intervention group, n = 17). The survey comprised questions about fertility-related knowledge, attitude towards FP, willingness to undergo FP and socio-demographic data, as well as the decisional conflict and decisional regret scales. Main results and the role of chance All participants showed low decisional conflict scores. Women who used the online DA in addition to counselling (intervention group) showed a significantly lower total score on the Decisional Conflict Scale (DCS) compared to the control group at T1 (P = 0.008; M = 12.15, SD = 4.38; 95% CI, 3.35–20.95) and at T2 (P = 0.043; M = 9.35, SD = 4.48; 95% CI, 0.31–18.38). At T3, the mean total score of the DCS was still lower in the intervention group compared to the control group; however, this group difference was no longer significant (P = 0.199, M = 6.86, SD = 5.24; 95% CI, −3.78 to 17.51). The majority of participants had already made a decision regarding FP (yes or no) at T1 (72.5%): 91.7% in the intervention group compared to 55.6% in the control group (P = 0.014). Those who had decided already at T1 showed significantly lower decisional conflict (P = 0.007; M = 13.69, SD = 4.89; 95% CI, 3.86–23.52). The average number of DA sessions per user was 2.23, and 80.8% of the participants completed the DA’s value clarification exercises. Participants in the intervention group were satisfied with the DA and would recommend it to other patients. Limitations, reasons for caution The recruitment of participants was challenging because of the emotionally difficult situation patients were in. This led to the limited sample size for final analysis. Education levels were high in two-thirds of the participants. It is difficult to say whether the DA would be equally effective in women with a lower educational background. Wider implications of the findings There is evidence that the DA served as a helpful complement to the decision-making process for young female cancer patients qualifying for FP. This is, to our knowledge, the first randomized controlled trial evaluating a DA targeted at patients with several cancer types and in a language other than English (i.e. German). This study contributes to extending the range of the still limited number of DAs in the context of FP. Study funding/competing interest(s) The study was supported by a research grant of the Swiss Cancer Research. The authors declare that no competing interests exist. Trial registration number Clinicaltrials.gov, trial no. NCT02404883. Trial registration date 19 March 2015 Date of first patient’s enrolment 4 July 2016


2011 ◽  
Vol 19 (12) ◽  
pp. 1909-1919 ◽  
Author(s):  
Katharina Hancke ◽  
Vladimir Isachenko ◽  
Evgenia Isachenko ◽  
Jürgen M. Weiss

Sign in / Sign up

Export Citation Format

Share Document